News - Dainippon Sumitomo Pharma, Research

Filter

Popular Filters

Sunovion's eslicarbazepine successful in Ph III epilepsy studies

18-09-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

Dainippon Sumitomo PharmaeslicarbazepineNeurologicalPharmaceuticalResearchSunovion

Sunovion announces novel drug discovery partnership

14-08-2013

Sunovion Pharmaceuticals, a wholly-owned US subsidiary of Japanese drug major Dainippon Sumitomo Pharma…

AfraxisDainippon Sumitomo PharmaLicensingNeurologicalPharmaceuticalResearchSunovion

Dainippon Sumitomo establishes regenerative and cellular medicine office

12-08-2013

Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506) says that it has set up the Regenerative &…

Asia-PacificBiotechnologyDainippon Sumitomo PharmaPharmaceuticalProductionResearch

Dainippon Sumitomo gains rights to Edison Pharma drug candidates in up to $545 million accord

02-04-2013

Privately-held US firm Edison Pharmaceuticals has entered into a research, development and commercialization…

Dainippon Sumitomo PharmaEdison PharmaceuticalsEPI-589EPI-743LicensingNeurologicalPharmaceuticalResearch

Dainippon Sumitomo to set up DSP Cancer Institute

21-08-2012

Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506) says it plans to establish a new organization…

BiotechnologyDainippon Sumitomo PharmaManagementOncologyPharmaceuticalResearch

Dainippon Sumitomo's Latuda meets key endpoints in two Ph III trials in bipolar I depression

09-05-2012

Japanese drugmaker Dainippon Sumitomo Pharma (4506: JP) Co., Ltd. (DSP) announced has results from two…

Dainippon Sumitomo PharmaLatudaNeurologicalPharmaceuticalResearch

Back to top